STUB1 and myeloid neoplasm: Understanding the impact of inactivating TET2 and DNMT3A mutations on myeloid cells is critical for elucidating the connection between CHIP, inflammation, and the pathogenesis of comorbid disease, as well as myeloid malignancies.